21st Century Business Herald reporter Zhu Ping, Lin Yunxiao, Shi Xi Jiang Yifei reported from Beijing
@关于医药上市公司预警: Jinyao Pharmaceutical made provision for asset impairment, ST Jiyao disclosed the company's litigation progress, China Pharmaceutical employee supervisor resigned, and Yaoyeego Company's supervisor shareholding reduction plan expired.
@关于医药上市公司动态: In terms of consistency evaluation, Huana Pharmaceutical's drug diclofenac sodium sustained-release tablets, the drugs of China Pharmaceutical Subsidiary and the drugs of Lifang Pharmaceutical passed the consistency evaluation of the quality and efficacy of generic drugs respectively; CanSino adsorbed tetanus vaccine started phase I clinical trial and completed the enrollment of the first subject, Zhifei Biologics diphtheria-tetanus-pertussis vaccine entered phase III clinical trial; In terms of rectification dynamics, Nhwa Pharmaceutical announced that the US FDA closed the company's Jiawang API factory warning letter; in terms of share repurchase/pledge/transaction, Nanxin Pharmaceutical intends to repurchase the company's shares for 5 million yuan to 10 million yuan, and Zhenghai Biotech plans to repurchase the company's shares for 25 million yuan to 50 million yuan; Longjin Pharmaceutical Co., Ltd. used idle self-owned funds to purchase wealth management products.
Early warning of listed pharmaceutical companies
Tianjin Pharmaceutical Co., Ltd.: Provision for asset impairment
Tianjin Pharmaceutical Co., Ltd. announced on December 20 that the third meeting of the ninth board of directors and the third meeting of the ninth board of supervisors of the company respectively deliberated and passed the "Proposal on Provision for Asset Impairment". Tianjin Jinyao Environmental Technology Co., Ltd., a subsidiary of the company, is responsible for the company's energy supply, among which the ammonia refrigeration equipment currently used in the refrigeration station has extremely low operating efficiency and can no longer meet the normal cooling demand, and the ammonia refrigeration station equipment, refrigeration pipes, ammonia valves, etc. are seriously aging and have potential safety hazards. In order to meet the relevant requirements of safety supervision, solve the company's cooling needs, and eliminate safety and environmental protection risks from the root, the company plans to transform the refrigeration station, and the original 93 sets of ammonia-related equipment must be stopped and dismantled during the implementation of the transformation project. In order to accurately reflect the actual situation of the company's fixed assets, the company conducted an impairment test on the above 93 fixed assets based on the principle of prudence in accordance with the accounting standards for business enterprises and the relevant provisions of the company's financial management system, and made an impairment provision of 5.1832 million yuan for fixed assets.
ST Jiyao: Progress of the company's litigation
ST Jiyao announced on December 20 that the company recently received the "Enforcement Ruling" (2021) Ji 05 Zhi No. 146-7, the "Enforcement Ruling" (2021) Ji 05 Zhi No. 146-8, and the "Case Closure Notice" (2023) Ji 05 Zhi Hui No. 93 issued by the Intermediate People's Court of Tonghua City, Jilin Province. On October 23, 2023, the bank accounts under the names of Jilin Jinbao Pharmaceutical Co., Ltd., Jilin Pharmaceutical Holding Group Co., Ltd., Meihekou Jinbao Xinhua Hospital Management Co., Ltd., and Sun * were renewed, and on October 25, 2023, the real estate and land in the name of Jilin Jinbao Pharmaceutical Co., Ltd. were resealed, and on November 21, 2023, Jilin Jinbao Pharmaceutical Co., Ltd., Jilin Pharmaceutical Holding Group Co., Ltd., The deposit of 99,116.62 yuan in the account under the name of Meihekou Jinbao Xinhua Hospital Management Co., Ltd. was deducted and paid to the Tonghua Branch of China Merchants Bank Co., Ltd., the applicant for execution, so far, the execution of the resumption case has been completed.
China Pharmaceutical: Employee supervisor resigned
China Pharmaceutical announced on December 20 that recently, the board of supervisors of the company received a written resignation letter from Ms. Yao Dan, an employee supervisor, and Ms. Yao Dan applied for resignation from the company's employee supervisor due to work adjustment. After resigning as an employee supervisor, Ms. Yao Dan will continue to serve in the company's subsidiaries.
Yaoyebuy: The term of the company's supervisor's shareholding reduction plan has expired
Yaoyegou announced on December 20 that the company recently received a notification letter from Mr. Tian Wenwen, the company's supervisor, that the period of its shareholding reduction plan has expired, and 1,216,795 shares of the company will be reduced through centralized bidding, accounting for 1.271912% of the company's total share capital, and the actual number of shares reduced does not exceed the number of shares planned to be reduced.
Dynamics of listed pharmaceutical companies
- Consistency evaluation
Warner Pharmaceutical: The drug diclofenac sodium sustained-release tablets passed the consistency evaluation of generic drug quality and efficacy
Huana Pharmaceutical announced on December 20 that the company received the "Notice of Approval of Drug Supplementary Application" approved and issued by the State Drug Administration for diclofenac sodium sustained-release tablets, and after review, this product passed the consistency evaluation of generic drug quality and efficacy.
China Pharmaceutical: The subsidiary's drugs passed the consistency evaluation of the quality and efficacy of generic drugs
China Pharmaceutical announced on December 20 that Hainan General Sanyo Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received a "Notice of Approval of Supplementary Application for Drugs" for amoxicillin granules approved and issued by the State Drug Administration, and the drug passed the consistency evaluation of generic drug quality and efficacy.
Lifang Pharmaceutical: The drug passed the consistency evaluation
Lifang Pharmaceutical announced on December 20 that the company received the "Notice of Approval of Supplementary Application for Drugs" for metformin glipizide tablets approved and issued by the State Drug Administration. The company's metformin glipizide tablets have passed the consistency evaluation of generic drug quality and efficacy.
- R&D/Clinical/Market Progress
Zhongguancun: Duoduo Pharmaceutical Montmorillonite Powder obtained the "Drug Registration Certificate"
Zhongguancun announced on December 20 that the company's subsidiary, Duoduo Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" with the certificate number 2023S02007 approved and issued by the State Drug Administration, and the "montmorillonite powder" (specification: each bag contains 3 grams of montmorillonite) developed by Duoduo Pharmaceutical passed the generic drug registration application.
China Biologics: China's first rare disease treatment drug produced using genetically modified animals has been approved for clinical trials
On December 20, China Biologics reported on its official WeChat that on December 15, the "recombinant human C1 esterase inhibitor" developed by the Chengdu Institute of Biological Products of Sinopharm Group was awarded the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration. The drug is the first therapeutic drug in China to be approved for clinical research using genetically modified animals. Human C1 esterase inhibition is mainly used for the treatment of acute-onset hereditary angioedema in adults and adolescents.
Hengrui Pharmaceutical: Obtained the "Notice of Approval of Drug Clinical Trials"
Hengrui Pharmaceutical announced on December 20 that the company received the approval of the State Drug Administration to issue the "Drug Clinical Trial Approval Notice" for SHR2554 tablets. SHR2554 Tablets is a novel, highly potent, and selective oral EZH2 inhibitor developed by the Company for the treatment of malignant tumors.
Hengrui Pharmaceutical announced on December 20 that the company received the approval of the State Drug Administration (hereinafter referred to as the "State Food and Drug Administration") to issue the "Drug Clinical Trial Approval Notice" on SHR0302 sustained-release tablets, and will carry out clinical trials in the near future. SHR0302 extended-release tablets are highly selective JAK1 inhibitors that exert anti-inflammatory and immune-suppressing biological effects by inhibiting JAK1 signaling.
CanSino: Initiated phase I clinical trial of adsorbed tetanus vaccine and completed the enrollment of the first subject
CanSino announced on December 20 that the company's adsorbed tetanus vaccine officially launched the phase I clinical trial recently and completed the enrollment of the first subject.
Zhifei Biotech: Component 100 diphtheria-tetanus-pertussis vaccine entered phase III clinical trials
Zhifei Biotech announced on December 20 that the company recently learned that the adsorbed acellular diphtheria-pertussis (component) combination vaccine independently developed by Beijing Zhifei Luzhu Biopharmaceutical Co., Ltd., a wholly-owned subsidiary, has carried out phase III clinical trials in Guangxi.
- Rectification dynamics
Nhwa Pharmaceutical: The U.S. FDA closed the company's Jiawang API factory warning letter
Nhwa announced on December 20 that recently, the company received an official email notification from the U.S. Food and Drug Administration ("FDA") that the FDA has completed the evaluation of the corrective measures for the deficiencies proposed in the company's warning letter on September 10, 2019, and believes that the company has taken corresponding corrective actions for the deficiencies proposed in the warning letter, so the warning letter to the company's Jiawang API factory has been closed.
- Share buyback/pledge/transaction
Nanxin Pharmaceutical: It is planned to repurchase the company's shares for 5 million yuan to 10 million yuan
Nanxin Pharmaceutical announced on December 20 that the company intends to repurchase the company's shares with 5 million yuan to 10 million yuan, and the repurchase price will not exceed 15.85 yuan per share.
Zhenghai Biological: It is planned to repurchase the company's shares for 25 million yuan to 50 million yuan
Zhenghai Biotech announced on December 20 that the company intends to use its own funds to repurchase the company's shares for equity incentives or employee stock ownership plans with 25 million yuan to 50 million yuan through centralized bidding, and the repurchase price does not exceed 44.90 yuan per share.
- Money management
Haite Bio: Use idle own funds to purchase wealth management products
Haite Biotech announced on December 20 that the 14th meeting of the 8th board of directors and the 14th meeting of the 8th board of supervisors of the company reviewed and approved the "Proposal on the Use of Idle Raised Funds and Own Funds for Cash Management", and agreed that the company should use no more than RMB 110,000 to purchase low-risk wealth management products with an investment period of no more than 12 months, high security and good liquidity under the condition of ensuring that the construction of the investment project of the raised funds is not affected, the normal operation is not affected and the safety of the funds is ensured. Among them, the use of idle raised funds shall not exceed RMB450 million, and the use of own funds shall not exceed RMB650 million. Within the above limit, the funds can be used on a rolling basis for a period of 1 year.
Longjin Pharmaceutical: Use idle own funds for cash management
Longjin Pharmaceutical announced on December 20 that the company held the 14th meeting of the fifth board of directors on December 5, 2022 and the third extraordinary general meeting of shareholders in 2022 on December 21, 2022, and deliberated and passed the "Proposal on the Use of Idle Own Funds for Cash Management", and agreed that the balance of the company and its subsidiaries included in the company's consolidated statements should not exceed RMB 350 million (35,000 10,000 yuan) of its own idle funds for cash management, investment varieties include structured deposits, wealth management products, income certificates, collective asset management (trust) plans, money market funds, treasury bonds, treasury bonds reverse repurchase and other low-risk and liquid products, the company's general meeting of shareholders authorized the board of directors and management to be responsible for the specific implementation of related matters, the authorization period is from the date of approval of the general meeting of shareholders to within one year.
- Interactive platform
Fudan Fuhua: Responding to questions about market performance
Fudan Fuhua responded to investors' questions about market performance on the interactive platform on December 20, saying that the company suffered losses from 2020 to 2022 due to the impact of asset impairment provisions and multiple unexpected factors of shareholding companies.
For more information, please download the 21 Finance APP